asa guidelines for glp-1 New therapeutic agents type 2 diabetes: anaesthetic considerations. A narrative review The 2023 ASA position on

In January, a more affordable, easy-to-administer oral version of the drug became available in the U.S., with a second brand following suit in early April

Probably minor

Lyophilized compounds are packaged for stability

Exenatide and liraglutide additionally lowered the expression of other apoptosis-related proteins, including poly (ADP-ribose) polymerase (PARP), caspase-8, caspase-9, and Bcl-2-associated death promoter (Bad) [87, 92]

(2006) GLP-1/exendin-4 facilitates -cell neogenesis in rat and human pancreatic ducts

The benefits of these medications for glycaemic control and cardiovascular risk reduction generally outweigh the potential pancreatic risks in appropriately selected patients